May 19-20, 2017
Saint Petersburg, Russia
Organizers:
Russian Society of Clinical Oncology (RUSSCO), Russia
Kidney Cancer Association, USA
Registration and abstract submission (deadline: 1 May 2017)
Admission: Free
Russian visa: RUSSCO will provide visa support documents
Program
May 19, 2017
12:30-14:00 – Young oncologists session
14:00 – Opening ceremony
RUSSCO’s address (Prof. D. Nosov)
Kidney Cancer Association’s address (Carolyn Konosky, MBA)
Session 1
Chairs:
Prof. S. Petrov (Saint Petersburg)
Prof. V. Atduev (Nizhny Novgorod)
14:10-14:40 – Impossible is nothing: presentation and discussion of complicated clinical cases
(clinical case presentations with interactive voting, 15 minutes each)
– Clinical case 1: surgical treatment – Prof. V. Matveev (Moscow)
– Clinical case 2: surgical treatment – Prof. G. Bratslavsky (Syracuse, USA)
14:40-14:45 – Questions
14:45-15:05 – Preoperative 3D planning as a navigation in renal surgery
Dr. E. Shpot, PhD (Moscow)
15:05-15:10 – Questions
15:10-15:30 – Repeat ipsilateral parcial nephrectomy in patients with RCC recurrence:
– Treatment of choice – Prof. G. Bratslavsky (Syracuse, USA)
– Baseless – Prof. V. Matveev (Moscow)
15:30-15:35 – Questions
15:35-15:55 – Management of T1 stage papillary and chromophobe renal cell carcinoma:
– Active surveillance – Dr. V. Chernyaev, PhD (Moscow)
– Partial nephrectomy – Dr. R. Leonenkov, PhD (Saint Petersburg)
15:55-16:00 – Questions
16:00-16:20 – Role of minimally invasive approaches in the treatment of localized RCC
Dr. А. Nosov, PhD (Saint Petersburg)
16:20-16:25 – Questions
16:25-16:50 – Coffee Break
Session 2
Chairs:
Prof. V. Matveev (Moscow)
Prof. R. Zukov (Krasnoyarsk)
16:50-17:05 – Renal cell carcinoma in adolescents and young adults: is there any difference in approach?
Dr. P. Borisov, PhD (Saint Petersburg)
17:05-17:10 – Questions
17:10-17:30 – Neoadjuvant therapy in patients with M0 stage: where are we in 2017?
Dr. М. Volkova, PhD (Moscow)
17:30-17:35 – Questions
17:35-17:55 – Is there a place of adjuvant therapy in the current treatment strategy for high-risk RCC patients?
– Pro – Prof. B. Alekseev (Moscow)
– Contra – Dr. R. Gafanov, PhD (Moscow)
17:55-18:00 – Questions
18:00-19:00 – Satellite Symposia
19:00-20:30 – Dinner
May 20, 2017
09:00-10:00 – Breakfast with Professor. Young Oncologists’ Committee
Prof. Gennady Bratslavsky (Syracuse, USA)
Session 3
Chairs:
Dr. D. Heng, MPH (Calgary, Canada)
Prof. R. Orlova (Saint Petersburg)
10:00-10:45 – Impossible is nothing: presentation and discussion of complicated clinical cases
(clinical case presentations with interactive voting, 15 minutes each)
– Clinical case 1: systemic therapy – Prof. A. Česas (Kaunas, Lithuania)
– Clinical case 2: systemic therapy – Dr. D. Heng, MPH (Calgary, Canada)
– Clinical case 3: systemic therapy – Prof. D. Nosov (Moscow)
10:45-10:55 – Questions
10:55-11:20 – How do I choose a treatment strategy for patient with newly diagnosed metastatic renal cell carcinoma?
Dr. D. Heng, MPH (Calgary, Canada)
11:20-11:25 – Questions
11:25-11:40 – Evaluation of response to therapy in clinical practice
Dr. F. Moiseenko, PhD (Saint Petersburg)
11:40-11:45 – Questions
11:45-12:00 – Coffee Break
Session 4
Chairs:
Prof. B. Alekseev (Moscow)
Prof. A. Alyasova (Nizhny Novgorod)
12:00-12:30 – Management for long-term disease stabilization achieved with targeted therapy in RCC patients:
– Metastasectomy
Dr. А. Popov, PhD (Moscow)
– SBRT – Dr. N. Dengina, PhD (Ulyanovsk)
– Surveillance – Prof. R. Zukov (Krasnoyarsk)
12:30-13:00 – Preferred mechanism of overcoming treatment resistance in mRCC is:
– Checkpoint inhibition – Dr. V. Neiman (Israel)
– Highly selective VEGFR tyrosine kinase inhibition – Dr. D. Heng, MPH (Calgary, Canada)
– Inhibition of other pathways (mTOR and FGFR) – Prof. James J. Hsieh (Washington, USA)
13:05-14:05 – Satellite Symposia
14:05-15:00 – Lunch
Session 5
Chairs:
Prof. D. Nosov (Moscow)
Prof. A. Česas (Kaunas, Lithuania)
15:00-15:15 – Treatment-induced fatigue: is it possible to overcome it and how?
Dr. V. Chubenko, PhD (Moscow)
15:15-15:30 – Gastrointestinal toxicities of targeted therapies and checkpoint inhibitors
Dr. М. Volkova, PhD (Moscow)
15:30-15:45 – Anemia in advanced RCC patients: when should it be alarming?
Dr. V. Chubenko, PhD (Moscow)
15:45-15:50 – Questions
15:50-16:15 – Is there a place for "non-conventional" agents in the management of patients with RCC: Metformin, Aspirin, Low molecular weight heparin
Dr. I. Tsimafeyeu, PhD (Moscow)
16:15-16:20 – Questions
16:20-16:50 – Review of current clinical trials:
In surgery – Prof. B. Alekseev (Moscow)
In systemic therapy – Dr. A. Kalpinsky (Moscow)
16:50-16:55 – Questions
17:00-18:00 – Satellite Symposia
Session 6
18:00-18:55 – Presentation of the selected abstracts
Chairs: rof. G. Bratslavsky (Syracuse, USA), Prof. D. Nosov (Moscow)
18:55-19:00 – RKCS closing ceremony
19:30-22:00 – Gala Dinner in the city
